1. Home
  2. BOSC vs NXTC Comparison

BOSC vs NXTC Comparison

Compare BOSC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo B.O.S. Better Online Solutions

BOSC

B.O.S. Better Online Solutions

HOLD

Current Price

$4.27

Market Cap

26.3M

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$11.90

Market Cap

24.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOSC
NXTC
Founded
1990
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
24.6M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
BOSC
NXTC
Price
$4.27
$11.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
132.7K
55.1K
Earning Date
11-25-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
35.29
N/A
EPS
0.51
N/A
Revenue
$48,333,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.27
N/A
Revenue Growth
19.49
N/A
52 Week Low
$3.14
$2.69
52 Week High
$6.72
$15.74

Technical Indicators

Market Signals
Indicator
BOSC
NXTC
Relative Strength Index (RSI) 37.82 54.01
Support Level $4.36 $10.81
Resistance Level $4.96 $12.49
Average True Range (ATR) 0.26 1.04
MACD -0.02 -0.23
Stochastic Oscillator 18.82 27.64

Price Performance

Historical Comparison
BOSC
NXTC

About BOSC B.O.S. Better Online Solutions

BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: